The journals that are reviewed and the criteria for selecting articles from these journals for inclusion in Evidence-Based Mental Health are set out in the purpose and procedure in each issue. All articles that meet our criteria in the reviewed journals are cited in Evidence-Based Mental Health, but there is not enough space to abstract them all. The following articles passed all criteria but were not abstracted because, in the judgment of the editors, their findings were less widely applicable to clinical practice in the area of mental health.
THERAPEUTICS
Bell M, Bryson G, Wexler BE. Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia. Acta Psychiatr Scand 2003 Aug;108:101–9.
Ernst E. Serious psychiatric and neurological adverse effects of herbal medicines—a systematic review. Acta Psychiatr Scand 2003 Aug;108:83–91.
Gilbody S, Whitty P, Grimshaw J, et al. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA 2003 Jun 18;289:3145–51
Januel D, Poirier MF, D’alche-Biree F, et al. Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. J Affect Disord 2003 Sep;76:191–200.
Jorm AF, Griffiths KM, Christensen H, et al. Providing information about the effectiveness of treatment options to depressed people in the community: a randomized controlled trial of effects on mental health literacy, help-seeking and symptoms. Psychol Med 2003 Aug;33:1071–9.
Ludman E, Katon W, Bush T, et al. Behavioural factors associated with symptom outcomes in a primary care-based depression prevention intervention trial. Psychol Med 2003 Aug;33:1061–70.
Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003 Jul;60:737–46.
Marder SR, Glynn SM, Wirshing WC, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003 Aug;160:1405–12.
Nose M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003 Sep;183:197–206.
Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003 Jul;160:1277–85.
Seidman LJ, Schutt RK, Caplan B, et al. The effect of housing interventions on neuropsychological functioning among homeless persons with mental illness. Psychiatr Serv 2003 Jun;54:905–8.
AETIOLOGY
Blumenthal JA, Lett HS, Babyak MA, et al. Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet 2003 Aug 23;362:604–9.
Kotimaa AJ, Moilanen I, Taanila A, et al. Maternal smoking and hyperactivity in 8-year-old children. J Am Acad Child Adolesc Psychiatry 2003 Jul;42:826–33.
Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003 Aug;160:1396–404.
Osborn DP, Fletcher AE, Smeeth L, et al. Factors associated with depression in a representative sample of 14 217 people aged 75 and over in the United Kingdom: results from the MRC trial of assessment and management of older people in the community. Int J Geriatr Psychiatry 2003 Jul;18:623–30.
Ruo B, Rumsfeld JS, Hlatky MA, et al. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003 Jul 9;290:215–21.
Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003 Jun 19;348:2508–16.
PROGNOSIS
DelBello MP, Carlson GA, Tohen M, et al. Rates and predictors of developing a manic or hypomanic episode 1 to 2 years following a first hospitalization for major depression with psychotic features. J Child Adolesc Psychopharmaco 2003 Summer;13:173–85.
Holtzer R, Wegesin DJ, Albert SM, et al. The rate of cognitive decline and risk of reaching clinical milestones in Alzheimer disease. Arch Neuro 2003 Aug;60:1137–42.